EMcision Ltd., a privately-held company headquartered in London, UK that develops and commercializes proprietary medical devices, today announced that it and its subsidiaries have been acquired by Boston Scientific, the world’s premier endoscopic devices company.
Founded by internationally renowned surgeon and inventor, Prof. Nagy Habib, EMcision develops innovative devices including the HabibTM 4X, the HabibTM EndoHPB and the HabibTM EUS RFA. Those products have benefited close to 100,000 patients suffering from cancers of the liver, pancreas and bile ducts.
EMcision’s flagship product, the HabibTM EndoHPB, was the world’s first endoscopic device for tumour ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma.
“Recently, two randomised clinical trials showed independently a statistically significant survival advantage for patients treated with the HabibTM EndoHPB,” said Prof. Nagy Habib, EMcision’s Chairman and founder. “This new treatment has empowered endoscopists with a very useful device for management of these unfortunate patients with advanced cancer.”
EMcision devices are sold in 38 countries around the world and used by surgeons and endoscopists in most of the top US cancer centres such as MD Anderson, Memorial Sloan Kettering, Mayo Clinic, Cleveland Clinic, Johns Hopkins, Massachusetts General and Stanford.
“By partnering with Boston Scientific, we will continue delivering on our mission of improving the quality of life of cancer patients on a much larger scale. Boston Scientific has the resources and the know-how to further improve our technology, expand clinical indications and make it available to many more patients,” said Cherif Habib, EMcision’s outgoing CEO.
Boston Scientific, headquartered in Marlborough, Massachusetts, was founded in 1979 and employs over 27,000 people. Their products, across six business divisions, treat over 24 million patients every year.
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.